Towards Predictive Computational Models of Oncolytic Virus Therapy: Basis for Experimental Validation and Model Selection

Oncolytic viruses are viruses that specifically infect cancer cells and kill them, while leaving healthy cells largely intact. Their ability to spread through the tumor makes them an attractive therapy approach. While promising results have been observed in clinical trials, solid success remains elusive since we lack understanding of the basic principles that govern the dynamical interactions between the virus and the cancer. In this respect, computational models can help experimental research at optimizing treatment regimes. Although preliminary mathematical work has been performed, this suffers from the fact that individual models are largely arbitrary and based on biologically uncertain assumptions. Here, we present a general framework to study the dynamics of oncolytic viruses that is independent of uncertain and arbitrary mathematical formulations. We find two categories of dynamics, depending on the assumptions about spatial constraints that govern that spread of the virus from cell to cell. If infected cells are mixed among uninfected cells, there exists a viral replication rate threshold beyond which tumor control is the only outcome. On the other hand, if infected cells are clustered together (e.g. in a solid tumor), then we observe more complicated dynamics in which the outcome of therapy might go either way, depending on the initial number of cells and viruses. We fit our models to previously published experimental data and discuss aspects of model validation, selection, and experimental design. This framework can be used as a basis for model selection and validation in the context of future, more detailed experimental studies. It can further serve as the basis for future, more complex models that take into account other clinically relevant factors such as immune responses.

[1]  F. McCormick,et al.  Cancer Specific Viruses and the Development of ONYX-015 , 2003, Cancer biology & therapy.

[2]  R. May,et al.  Infection dynamics on scale-free networks. , 2001, Physical review. E, Statistical, nonlinear, and soft matter physics.

[3]  J. Bell,et al.  Getting oncolytic virus therapies off the ground. , 2003, Cancer cell.

[4]  H. McCallum,et al.  How should pathogen transmission be modelled? , 2001, Trends in ecology & evolution.

[5]  A. Barabasi,et al.  Halting viruses in scale-free networks. , 2001, Physical review. E, Statistical, nonlinear, and soft matter physics.

[6]  Hyunsuk Shim,et al.  Cancer scene investigation: how a cold virus became a tumor killer. , 2005, Future oncology.

[7]  Eugene V Koonin,et al.  Mathematical modeling of tumor therapy with oncolytic viruses: Regimes with complete tumor elimination within the framework of deterministic models , 2006, Biology Direct.

[8]  R. Martuza,et al.  Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. , 1999, Neoplasia.

[9]  M. Begon,et al.  Transmission dynamics of a zoonotic pathogen within and between wildlife host species , 1999, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[10]  C. O'Shea,et al.  Viruses – seeking and destroying the tumor program , 2005, Oncogene.

[11]  Nicola Bellomo,et al.  A Survey of Models for Tumor-Immune System Dynamics , 1996 .

[12]  S. Russell,et al.  History of oncolytic viruses: genesis to genetic engineering. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  A. J. Hall Infectious diseases of humans: R. M. Anderson & R. M. May. Oxford etc.: Oxford University Press, 1991. viii + 757 pp. Price £50. ISBN 0-19-854599-1 , 1992 .

[14]  W. Rom,et al.  Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved--deletion of the viral E1b-19-kD gene increases the viral oncolytic effect. , 2001, Human gene therapy.

[15]  M. Roberts,et al.  Naturally oncolytic viruses. , 2006, Current opinion in molecular therapeutics.

[16]  Frank McCormick,et al.  Future prospects for oncolytic therapy , 2005, Oncogene.

[17]  R. Martuza,et al.  Oncolytic viral therapies – the clinical experience , 2005, Oncogene.

[18]  A. Barbour,et al.  Epidemics and random graphs , 1990 .

[19]  Duncan J. Watts,et al.  Collective dynamics of ‘small-world’ networks , 1998, Nature.

[20]  M. Newman Spread of epidemic disease on networks. , 2002, Physical review. E, Statistical, nonlinear, and soft matter physics.

[21]  J. Bell,et al.  Oncolytic viruses: what's next? , 2007, Current cancer drug targets.

[22]  J. Bell,et al.  Recent progress in the battle between oncolytic viruses and tumours , 2005, Nature Reviews Cancer.

[23]  Alessandro Vespignani,et al.  Epidemic dynamics and endemic states in complex networks. , 2001, Physical review. E, Statistical, nonlinear, and soft matter physics.

[24]  Dominik Wodarz,et al.  Gene therapy for killing p53-negative cancer cells: use of replicating versus nonreplicating agents. , 2003, Human gene therapy.

[25]  Mark D. F. Shirley,et al.  The impacts of network topology on disease spread , 2005 .

[26]  Jean-Pierre Gabriel,et al.  Stochastic Processes in Epidemic Theory , 1990 .

[27]  Simon Wain-Hobson Virus Dynamics: Mathematical Principles of Immunology and Virology , 2001, Nature Medicine.

[28]  M. Vähä-Koskela,et al.  Oncolytic viruses in cancer therapy , 2007, Cancer Letters.

[29]  Jianjun Paul Tian,et al.  Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. , 2006, Cancer research.

[30]  B. Fang,et al.  Oncolytic virotherapy for cancer treatment: challenges and solutions , 2005, The journal of gene medicine.

[31]  L. Ferrell,et al.  Expression of the coxsackievirus- and adenovirus receptor in gastrointestinal cancer correlates with tumor differentiation , 2006, Cancer Gene Therapy.

[32]  L. Meyers,et al.  When individual behaviour matters: homogeneous and network models in epidemiology , 2007, Journal of The Royal Society Interface.

[33]  F. Goodrum,et al.  The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle , 1997, Journal of virology.

[34]  J. Kaplan,et al.  Adenovirus-based cancer gene therapy. , 2005, Current gene therapy.

[35]  Dominik Wodarz,et al.  Computational approaches to study oncolytic virus therapy : insights and challenges , 2004 .

[36]  D. Kirn,et al.  Replicating viruses as selective cancer therapeutics. , 1996, Molecular medicine today.

[37]  S. Hotte,et al.  Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. , 2003, Current opinion in molecular therapeutics.

[38]  D. Kirn,et al.  From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. , 2007, Current cancer drug targets.

[39]  D. Wodarz,et al.  Viruses as antitumor weapons: defining conditions for tumor remission. , 2001, Cancer research.